AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: DESCOVY (Gilead Sciences) (descovy.com)
DESCOVY.COM is a high-substance pharmaceutical site that uses high-frequency repetition to drive home a singular clinical success metric. It successfully avoids the ‘hot air’ trap by tethering every major marketing claim to specific DISCOVER trial data, though it fails technical authority checks due to an absolute lack of structured data.
Eliminate the 14x repetition of the 99.7% H2 on the homepage to improve the heading hierarchy and user experience. Implement Product and Organization schema (JSON-LD) to link claims directly to clinical trial registry entries and Gilead’s corporate entity. Replace anecdotal ‘Real Stories’ headers with more descriptive context about the participant’s trial involvement. Provide direct outbound links to peer-reviewed publications of the DISCOVER trial results in the footer or clinical results page.
The site exhibits high information density with a low fluff-to-substance ratio, anchored by the specific claim ‘99.7% of people stayed HIV-negative.’ Substance is provided through clinical trial mentions (DISCOVER trial) and specific metrics regarding bone health and kidney function compared to Truvada. However, the homepage suffers from extreme concept repetition, restating the 99.7% statistic 14 times in H2 tags, which functions as a psychological mantra rather than providing new information.
If your @id chain is broken, your entire knowledge graph collapses into isolated nodes. Check your AI visible entity graph with a free one page structured data interpretation.
There is virtually zero semantic drift between the homepage signal and sub-page substance. The homepage H2 and H6 tags promise efficacy results from a ‘2-year study,’ and the ‘clinical-trial-efficacy-results’ page delivers exactly that, including specific comparative data on Bone Mineral Density (BMD) and renal labs. The transition from high-level efficacy to cost support ($0 per month) is logically consistent and supported by details on the Gilead Advancing Access program.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
Trust theatre is present on the ‘real-stories’ page, which triggers a trust_theatre_flag and a review_count of 1 without a corresponding proof_links_count. While the efficacy claims are tied to the DISCOVER trial, the ‘Real Stories’ section uses anecdotal personas like ‘Philip AKA Peachez’ and ‘Veronica’ without verified external proof paths or clinical trial participant IDs, shifting the burden of proof from data to sentiment.
The proof density is high, with 8+ instances of specific evidence including ‘99.7% stayed HIV-negative,’ ‘2-year study,’ ‘~96 weeks,’ and comparisons to ‘TRUVADA.’ This density of hard metrics significantly lowers the BS score despite the heavy marketing gloss and high repetition of the core value proposition.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
The site uses standard pharmaceutical template fingerprints such as ‘Important Safety Information,’ ‘Important Facts,’ and ‘You are leaving DESCOVY.COM’ warnings. Value proposition cliches like ‘Every DESCOVY user has a story’ and ‘DESCOVY Still Fits Their Lives’ are generic marketing tropes, but they are offset by highly unique drug-specific identifiers and patent-protected clinical outcomes that could not be copy-pasted onto a competitor.
A significant technical authority gap exists as the site contains null schema_json and zero evidence of structured data to support its ‘99.7%’ claim or organizational identity. While the brand is a pharmaceutical leader, the digital footprint lacks Person schema for the experts or medical professionals behind the clinical summaries, and the ‘Real Stories’ users lack any verifiable digital footprint beyond the site’s own content.
The performance claims are exceptionally bold (‘99.7%’) but, unlike typical marketing BS, these are anchored to a named clinical trial (DISCOVER) and a specific timeframe (~96 weeks). The disconnect is purely structural; the repetition of the claim is used to overwhelm the user, yet the underlying substance remains verifiable within the pharmaceutical regulatory context.
Medical Devices, Pharma & Biotech BS: DESCOVY (Gilead Sciences) (descovy.com)
The content perfectly aligns with the Pharma & Biotech industry, specifically the therapeutic area of HIV prevention (PrEP). All technical terminology such as ’emtricitabine and tenofovir alafenamide,’ ‘BMD,’ and ‘kidney function lab tests’ is industry-appropriate.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The BS score of 35 is primarily driven by Identity and Authority gaps (missing schema) and Trust Theatre (unverified reviews). The score is kept low by high Information Density and excellent Semantic Coherence, as the site provides hard clinical evidence for its primary marketing signals.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 29, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at DESCOVY (Gilead Sciences) to view the most current version of their content and see directly what the company offers.